NOVEL OXADIAZOLE COMPOUNDS CONTAINING 5-MEMBERED HETEROAROMATIC RING FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI FIELD OF THE INVENTION:

The present invention relates to novel oxadiazole compounds that are useful in combating phytopathogenic fungi, a process for preparing oxadiazoles, a combination and a composition comprising novel oxadiazoles. The present invention also relatesto a method for controlling or preventing phytopathogenic fungi.

BACKGROUNDOF THE INVENTION:

Oxadiazoles have already been disclosed in the literature. For example in EP3165093, WO2017076740, WO2017093019, WO2017093348, WO2017118689, WO2017162868, WO2017220485, WO2018118781, WO2018158365, WO2018184970,WO2018187553, WO2018202491, WO2019011923, WO2019012003, WO2019011926, WO2019011928, WO2019011929, WO2019012001 and WO2019012011 various oxadiazoles have been disclosed. The oxadiazole compounds reported in the above cited literature have disadvantages in certain aspects, such as that they exhibit a narrow spectrum of efficacy or that they do not have satisfactory fungicidal activity, particularly at low application rates.

Therefore, it is an object of the present invention to provide compounds having an improved/enhanced activity and/or a broader efficacy spectrum against phytopathogenic fungi.

This objective is achieved by using a compound of formula (I) of the present invention for controlling or preventing phytopathogenic fungi.

SUMMARYOF THE INVENTION:

The present invention relates to a compound of formula (I),

wherein,

R1, A, A5, A6, A7, A8, R12, n and Q are as defined in the detailed description. The present invention also relates to a process for preparing the compound of formula (I).

The compounds of formula (I) have been found to be advantageous over the compounds reported in the literature in either of improved fungicidal activity, broader spectrum of biological efficacy, lower application rates, more favourable biological, environmental properties or enhanced plant compatibility.

The present invention further relates to a combination comprising the compound of formula (I) of the present invention and at least one further pesticidally active substance for effectively controlling or preventing phytopathogenic fungi which are difficult to combat.

The present invention still further relates to anagrochemical composition comprising the compound of formula (I) as such or the compound of formula (I) in combination with a further pesticidally active substance.

The present invention still further relates to a method and use of the compound of formula (I) as suchor the combination or the composition thereof for controlling and or preventing plant diseases, particularly phtopathogenic fungi.

DETAILED DESCRIPTIONOF THE INVENTION:

DEFINITIONS:

The definitions provided herein for the terminologies used in the present disclosure are for illustrative purpose only and in no manner limit the scope of the present invention disclosed in the present disclosure.

As used herein, the terms “comprises”, “comprising”, “includes”, “including”, “has”, “having”, “contains”, “containing”, “characterized by” or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated. For example, a composition, mixture, process or method that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process or method.

The transitional phrase “consisting of” excludes any element, step or ingredient not specified. If in the claim, such would close the claim to the inclusion of materials other than those recited except for impurities ordinarily associated therewith. When the phrase “consisting of” appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole.

The transitional phrase “consisting essentially of” is used to define a composition or method that includes materials, steps, features, components or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components or elements do not materially affect the basic and novel characteristic(s) of the claimed invention. The term “consisting essentially of” occupies a middle ground between “comprising” and “consisting of”.

Further, unless expressly stated to the contrary, “or” refers to an inclusive “or” and not to an exclusive “or”. For example, a condition A “or” B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).

Also, the indefinite articles “a” and “an” preceding an element or component of the present invention are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore “a” or “an” should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular.

As referred to in this disclosure, the term “invertebrate pest” includes arthropods, gastropods and nematodes and helminths of economic importance as pests. The term “arthropod” includes insects, mites, spiders, scorpions, centipedes, millipedes, pill bugs and symphylans. The term “gastropod” includes snails, slugs and other Stylommatophora. The term “nematode” refers to a living organism of the Phylum Nematoda. The term “helminths” includes roundworms, heartworms, phytophagous nematodes (Nematoda), flukes (Tematoda), acanthocephala and tapeworms (Cestoda).

In the context of this disclosure “invertebrate pest control” means inhibition of invertebrate pest development (including mortality, feeding reduction, and/or mating disruption), and related expressions are defined analogously.

The term “agronomic” refers to the production of field crops such as for food, feed and fiber and includes the growth of corn, soybeans and other legumes, rice, cereal (e.g., wheat, oats, barley, rye, rice, maize), leafy vegetables (e.g., lettuce, cabbage, and other cole crops), fruiting vegetables (e.g., tomatoes, pepper, eggplant, crucifers and cucurbits), potatoes, sweet potatoes, grapes, cotton, tree fruits (e.g., pome, stone and citrus), small fruit (berries, cherries) and other specialty crops (e.g., canola, sunflower, olives).

The term “nonagronomic” refers to other than field crops, such as horticultural crops (e.g., greenhouse, nursery or ornamental plants not grown in a field), residential, agricultural, commercial and industrial structures, turf (e.g., sod farm, pasture, golf course, lawn, sports field, etc.), wood products, stored product, agro-forestry and vegetation management, public health (i.e. human) and animal health (e.g., domesticated animals such as pets, livestock and poultry, undomesticated animals such as wildlife) applications.

Nonagronomic applications include protecting an animal from an invertebrate parasitic pest by administering a parasiticidally effective (i.e. biologically effective) amount of a compound of the present invention, typically in the form of a composition formulated for veterinary use, to the animal to be protected. As referred to in the present disclosure and claims, the terms “parasiticidal” and “parasiticidally” refers to observable effects on an invertebrate parasite pest to provide protection of an animal from the pest. Parasiticidal effects typically relate to diminishing the occurrence or activity of the target invertebrate parasitic pest. Such effects on the pest include necrosis, death, retarded growth, diminished mobility or lessened ability to remain on or in the host animal, reduced feeding and inhibition of reproduction. These effects on invertebrate parasite pests provide control (including prevention, reduction or elimination) of parasitic infestation or infection of the animal.

Compounds of the present disclosure may be present either in pure form or as mixtures of different possible isomeric forms such as stereoisomers or constitutional isomers. The various stereoisomers include enantiomers, diastereomers, chiral isomers, atropisomers, conformers, rotamers, tautomers, optical isomers, polymorphs, and geometric isomers. Any desired mixtures of these isomers fall within the scope of the claims of the present disclosure. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other isomer(s) or when separated from the other isomer(s). Additionally, the person skilled in the art knows processes or methods or technology to separate, enrich, and/or to selectively prepare said isomers.

The meaning of various terms used in the description shall now be illustrated.

The term “alkyl”, used either alone or in compound words such as “alkylthio” or “haloalkyl” or -N(alkyl) or alkylcarbonylalkyl or alkylsuphonylamino includes straight-chain or branched C1 to C24 alkyl, preferably C1 to C15 alkyl, more preferably C1 to C10 alkyl, most preferably C1 to C6 alkyl. Non-limiting examples of alkyl include methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and l-ethyl-2-methylpropyl or the different isomers. If the alkyl is at the end of a composite substituent, as, for example, in alkylcycloalkyl, the part of the composite substituent at the start, for example the cycloalkyl, may be mono- or polysubstituted identically or differently and independently by alkyl. The same also applies to composite substituents in which other radicals, for example alkenyl, alkynyl, hydroxy, halogen, carbonyl, carbonyloxy and the like, are at the end.

The term “alkenyl”, used either alone or in compound words includes straight-chain or branched C2 to C24 alkenes, preferably C2 to C15 alkenes, more preferably C2 to C10 alkenes, most preferably C2 to C6 alkenes. Non-limiting examples of alkenes include ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-l-propenyl, l-methyl-2 -propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, l-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, l-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-1-propenyl, 1,2-dimethyl-2 -propenyl, 1-ethyl-1-propenyl, l-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, l-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, l,l-dimethyl-3-butenyl, 1,2-dimethyl-l-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-1-butenyl, l,3-dimethyl-2-butenyl, l,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-1-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-l-butenyl, 3,3-dimethyl-2-butenyl, 1-ethyl-1-butenyl, 1-ethyl-2-butenyl, l-ethyl-3-butenyl, 2-ethyl- 1-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, l,l,2-trimethyl-2-propenyl, 1-ethyl-l-methyl-2-propenyl, l-ethyl-2-methyl-l-propenyl and l-ethyl-2-methyl-2-propenyl and the different isomers. “Alkenyl” also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl. This definition also applies to alkenyl as a part of a composite substituent, for example haloalkenyl and the like, unless defined specifically elsewhere.

Non-limiting examples of alkynes include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, l-methyl-2-butynyl, l-methyl-3-butynyl, 2-methyl-3-butynyl, 3-methyl-l-butynyl, 1,1-dimethyl-2-propynyl, 1-ethyl -2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, l-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-l-pentynyl, 3-methyl-4-pentynyl, 4-methyl-l-pentynyl, 4-methyl-2-pentynyl, 1,1-dimethyl-2-butynyl, l,l-dimethyl-3-butynyl, l,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 3,3-dimethyl-l-butynyl, l-ethyl-2-butynyl, l-ethyl-3-butynyl, 2-ethyl-3-butynyl and 1-ethyl-l-methyl-2-propynyl and the different isomers. This definition also applies to alkynyl as a part of a composite substituent, for example haloalkynyl etc., unless specifically defined elsewhere. The term “alkynyl” can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl.

The term “cycloalkyl” means alkyl closed to form a ring. Non-limiting examples include cyclopropyl, cyclopentyl and cyclohexyl. This definition also applies to cycloalkyl as a part of a composite substituent, for example cycloalkylalkyl etc., unless specifically defined elsewhere.

The term “cycloalkenyl” means alkenyl closed to form a ring including monocyclic, partially unsaturated hydrocarbyl groups. Non-limiting examples include cyclopropenyl, cyclopentenyl and cyclohexenyl. This definition also applies to cycloalkenyl as a part of a composite substituent, for example cycloalkenylalkyl etc., unless specifically defined elsewhere.

The term “cycloalkynyl” means alkynyl closed to form a ring including monocyclic, partially unsaturated groups. Non-limiting examples include cyclopropynyl, cyclopentynyl and cyclohexynyl. This definition also applies to cycloalkynyl as a part of a composite substituent, for example cycloalkynylalkyl etc., unless specifically defined elsewhere.

The term “cycloalkoxy”, “cycloalkenyloxy” and the like are defined analogously. Non limiting examples of cycloalkoxy include cyclopropyloxy, cyclopentyloxy and cyclohexyloxy. This definition also applies to cycloalkoxy as a part of a composite substituent, for example cycloalkoxy alkyl etc., unless specifically defined elsewhere.

The term “halogen”, either alone or in compound words such as “haloalkyl”, includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as “haloalkyl”, said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Non-limiting examples of “haloalkyl” include chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl, 1,1-dichloro-2,2,2-trifluoroethyl, and 1,1,1-trifluoroprop-2-yl. This definition also applies to haloalkyl as a part of a composite substituent, for example haloalkylaminoalkyl etc., unless specifically defined elsewhere.

The terms “haloalkenyl”, “haloalkynyl” are defined analogously except that, instead of alkyl groups, alkenyl and alkynyl groups are present as a part of the substituent.

The term “haloalkoxy” means straight-chain or branched alkoxy groups where some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as specified above. Non-limiting examples of haloalkoxy include chloromethoxy, bromomethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 1-chloroethoxy, 1-bromoethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy and l,l,l-trifluoroprop-2-oxy. This definition also applies to haloalkoxy as a part of a composite substituent, for example haloalkoxyalkyl etc., unless specifically defined elsewhere.

The term “haloalkylthio” means straight-chain or branched alkylthio groups where some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as specified above. Non-limiting

examples of haloalkylthio include chloromethylthio, bromomethylthio, dichloromethylthio, trichloromethylthio, fluoromethylthio, difluoromethylthio, trifluoromethylthio, chlorofluoromethylthio, dichlorofluoromethylthio, chlorodifluoromethylthio, 1-chloroethylthio, 1-bromoethylthio, 1- fluoroethylthio, 2-fluoroethylthio, 2,2-difluoroethylthio, 2,2,2-trifluoroethylthio, 2-chloro-2- fluoroethylthio, 2-chloro-2,2-difluoroethylthio, 2,2-dichloro-2-fluoroethylthio, 2,2,2-trichloroethylthio, pentafluoroethylthio and l,l,l-trifluoroprop-2-ylthio. This definition also applies to haloalkylthio as a part of a composite substituent, for example haloalkylthioalkyl etc., unless specifically defined elsewhere.

Non-limiting examples of “haloalkylsulfinyl” include CF3S(O), CCl3S(O), CF3CH2S(O) and CF3CF2S(O). Non-limiting examples of “haloalkylsulfonyl” include CF3S(O)2, CCl3S(O)2, CF3CH2S(O)2 and CF3CF2S(O)2.

The term “hydroxy” means –OH, Amino means –NRR, wherein R can be H or any possible substituent such as alkyl. Carbonyl means -C(=O)- , carbonyloxy means -OC(=O)-, sulfinyl means SO, sulfonyl means S(O)2.

The term “alkoxy” used either alone or in compound words included C1 to C24 alkoxy, preferably C1 to C15 alkoxy, more preferably C1 to C10 alkoxy, most preferably C1 to C6 alkoxy. Examples of alkoxy include methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, 1,1-dimethylethoxy, pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, hexoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 1-methylpentoxy, 2-methylpentoxy, 3-methylpentoxy, 4-methylpentoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2-trimethylpropoxy, 1-ethyl-1-methylpropoxy and l-ethyl-2-methylpropoxy and the different isomers. This definition also applies to alkoxy as a part of a composite substituent, for example haloalkoxy, alkynylalkoxy, etc., unless specifically defined elsewhere.

The term “alkoxyalkyl” denotes alkoxy substitution on alkyl. Non-limiting examples of “alkoxyalkyl” include CH3OCH2, CH3OCH2CH2, CH3CH2OCH2, CH3CH2CH2CH2OCH2 and CH3CH2OCH2CH2. The term “alkoxyalkoxy” denotes alkoxy substitution on alkoxy.

The term “alkylthio” includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio, 1,1-dimethylethylthio, pentylthio, 1-methylbutylthio, 2-methylbutylthio, 3-methylbutylthio, 2,2-dimethylpropylthio, 1-ethylpropylthio, hexylthio, 1,1-dimethylpropylthio, 1,2-dimethylpropylthio, 1-methylpentylthio, 2-methylpentylthio, 3-methylpentylthio, 4-methylpentylthio, 1,1-dimethylbutylthio, 1,2-dimethylbutylthio, 1,3-dimethylbutylthio, 2,2-dimethylbutylthio, 2,3-dimethylbutylthio, 3,3-dimethylbutylthio, 1-ethylbutylthio, 2-ethylbutylthio, 1,1,2-trimethylpropylthio, 1,2,2-

trimethylpropylthio, 1-ethyl-1-methylpropylthio and l-ethyl-2-methylpropylthio and the different isomers.

Halocycloalkyl, halocycloalkenyl, alkylcycloalkyl, cycloalkylalkyl, cycloalkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, haloalkylcarbonyl, cycloalkylcarbonyl, haloalkoxylalkyl, and the like, are defined analogously to the above examples.

The term “alkylthioalkyl” denotes alkylthio substitution on alkyl. Non-limiting examples of “alkylthioalkyl” include -CH2SCH2, -CH2SCH2CH2, CH3CH2SCH2, CH3CH2CH2CH2SCH2 and CH3CH2SCH2CH2. “Alkylthioalkoxy” denotes alkylthio substitution on alkoxy. The term “cycloalkylalkylamino” denotes cycloalkyl substitution on alkyl amino.

The terms “alkoxyalkoxyalkyl”, “alkylaminoalkyl”, “dialkylaminoalkyl”, “cycloalkylaminoalkyl”, “cycloalkylaminocarbonyl” and the like, are defined analogously to “alkylthioalkyl” or “cycloalkylalkylamino”.

The term “alkoxycarbonyl” is an alkoxy group bonded to a skeleton via a carbonyl group (-CO-). This definition also applies to alkoxycarbonyl as a part of a composite substituent, for example cycloalkylalkoxycarbonyl and the like, unless specifically defined elsewhere.

The term “alkoxycarbonylalkylamino” denotes alkoxy carbonyl substitution on alkyl amino. “Alkylcarbonylalkylamino” denotes alkyl carbonyl substitution on alkyl amino. The terms alkylthioalkoxycarbonyl, cycloalkylalkylaminoalkyl and the like are defined analogously.

Non-limiting examples of “alkylsulfinyl” include methylsulphinyl, ethylsulphinyl, propylsulphinyl, 1-methylethylsulphinyl, butylsulphinyl, 1-methylpropylsulphinyl, 2-methylpropylsulphinyl, 1,1-dimethylethylsulphinyl, pentylsulphinyl, 1-methylbutylsulphinyl, 2-methylbutylsulphinyl, 3-methylbutylsulphinyl, 2,2-dimethylpropylsulphinyl, 1-ethylpropylsulphinyl, hexylsulphinyl, 1,1-dimethylpropylsulphinyl, 1,2-dimethylpropylsulphinyl, 1-methylpentylsulphinyl, 2-methylpentylsulphinyl, 3-methylpentylsulphinyl, 4-methylpentylsulphinyl, 1,1-dimethylbutylsulphinyl, 1,2-dimethylbutylsulphinyl, 1,3-dimethylbutylsulphinyl, 2,2-dimethylbutylsulphinyl, 2,3-dimethylbutylsulphinyl, 3,3-dimethylbutylsulphinyl, 1-ethylbutylsulphinyl, 2-ethylbutylsulphinyl, 1,1,2-trimethylpropylsulphinyl, 1,2,2-trimethylpropylsulphinyl, 1-ethyl-1-methylpropylsulphinyl and 1-ethyl-2-methylpropylsulphinyl and the different isomers. The term “arylsulfinyl” includes Ar-S(O), wherein Ar can be any carbocyle or heterocylcle. This definition also applies to alkylsulphinyl as a part of a composite substituent, for example haloalkylsulphinyl etc., unless specifically defined elsewhere.

Non-limiting examples of “alkylsulfonyl” include methylsulphonyl, ethylsulphonyl, propylsulphonyl, 1-methylethylsulphonyl, butylsulphonyl, 1-methylpropylsulphonyl, 2-methylpropylsulphonyl, 1,1-dimethylethylsulphonyl, pentylsulphonyl, 1-methylbutylsulphonyl, 2-methylbutylsulphonyl, 3-

methylbutylsulphonyl, 2,2-dimethylpropylsulphonyl, 1-ethylpropylsulphonyl, hexylsulphonyl, 1,1-dimethylpropylsulphonyl, 1,2-dimethylpropylsulphonyl, 1-methylpentylsulphonyl, 2-methylpentylsulphonyl, 3-methylpentylsulphonyl, 4-methylpentylsulphonyl, 1,1-dimethylbutylsulphonyl, 1,2-dimethylbutylsulphonyl, 1,3-dimethylbutylsulphonyl, 2,2-dimethylbutylsulphonyl, 2,3-dimethylbutylsulphonyl, 3,3-dimethylbutylsulphonyl, 1-ethylbutylsulphonyl, 2-ethylbutylsulphonyl, 1,1,2-trimethylpropylsulphonyl, 1,2,2-trimethylpropylsulphonyl, 1-ethyl-1-methylpropylsulphonyl and l-ethyl-2-methylpropylsulphonyl and the different isomers. The term “arylsulfonyl” includes Ar-S(O)2, wherein Ar can be any carbocyle or heterocylcle. This definition also applies to alkylsulphonyl as a part of a composite substituent, for example alkylsulphonylalkyl etc., unless defined elsewhere.

“Alkylamino”, “dialkylamino”, and the like, are defined analogously to the above examples.

The term “carbocycle or carbocyclic” includes “aromatic carbocyclic ring system” and “non-aromatic carbocylic ring system” or polycyclic or bicyclic (spiro, fused, bridged, nonfused) ring compounds in which ring may be aromatic or non-aromatic (where aromatic indicates that the Huckel rule is satisfied and non-aromatic indicates that the Huckel rule is not statisfied).

The term “heterocycle or heterocyclic” includes “aromatic heterocycle or heteroaryl ring system” and “non-aromatic heterocycle ring system” or polycyclic or bicyclic (spiro, fused, bridged, nonfused) ring compounds in which ring may be aromatic or non-aromatic, wherein the heterocycle ring contains at least one heteroatom selected from N, O, S(O)0-2, and or C ring member of the heterocycle may be replaced by C(=O), C(=S), C(=CR*R*) and C=NR*, * indicates integers.

The term “non-aromatic heterocycle” or “non-aromatic heterocyclic” means three- to fifteen-membered, preferably three- to twelve- membered, saturated or partially unsaturated heterocycle containing one to four heteroatoms from the group of oxygen, nitrogen and sulphur: mono, bi- or tricyclic heterocycles which contain, in addition to carbon ring members, one to three nitrogen atoms and/or one oxygen or sulphur atom or one or two oxygen and/or sulphur atoms; if the ring contains more than one oxygen atom, they are not directly adjacent; non-limiting examples oxetanyl, oxiranyl, aziridinyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-isoxazolidinyl, 4-isoxazolidinyl, 5-isoxazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5-isothiazolidinyl, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2-oxazolidinyl, 4-oxazolidinyl, 5-oxazolidinyl, 2-thiazolidinyl, 4-thiazolidinyl, 5-thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 1,2,4-oxadiazolidin-3-yl, l,2,4-oxadiazolidin-5-yl, l,2,4-thiadiazolidin-3-yl, 1,2,4-thiadiazolidin-5-yl, l,2,4-triazolidin-1-yl, l,2,4-triazolidin-3-yl, l,3,4-oxadiazolidin-2-yl, l,3,4-thiadiazolidin-2-yl, 1,3,4-triazolidin-1-yl, 1,3,4-triazolidin-2-yl, 2,3-dihydrofur-2-yl, 2,3-dihydrofur-3-yl, 2,4-dihydrofur-2-yl, 2,4-dihydrofur-3-yl, 2,3-dihydrothien-2-yl, 2,3-dihydrothien-3-yl, 2,4-dihydrothien-2-yl, 2,4-

dihydrothien-3-yl, pyrrolinyl, 2-pyrrolin-2-yl, 2-pyrrolin-3-yl, 3-pyrrolin-2-yl, 3-pyrrolin-3-yl, 2-isoxazolin-3-yl, 3-isoxazolin-3-yl, 4-isoxazolin-3-yl, 2-isoxazolin-4-yl, 3-isoxazolin-4-yl, 4-isoxazolin-4-yl, 2-isoxazolin-5-yl, 3-isoxazolin-5-yl, 4-isoxazolin-5-yl, 2-isothiazolin-3-yl, 3-isothiazolin-3-yl, 4-isothiazolin-3-yl, 2-isothiazolin-4-yl, 3-isothiazolin-4-yl, 4-isothiazolin-4-yl, 2-isothiazolin-5-yl, 3-isothiazolin-5-yl, 4-isothiazolin-5-yl, 2,3-dihydropyrazol-l-yl, 2,3-dihydropyrazol-2-yl, 2,3-dihydropyrazol-3-yl, 2,3-dihydropyrazol-4-yl, 2,3-dihydropyrazol-5-yl, 3,4-dihydropyrazol-l-yl, 3,4-dihydropyrazol-3-yl, 3,4-dihydropyrazol-4-yl, 3,4-dihydropyrazol-5-yl, 4,5-dihydropyrazol-l-yl, 4,5-dihydropyrazol-3-yl, 4,5-dihydropyrazol-4-yl, 4,5-dihydropyrazol-5-yl, 2,3-dihydrooxazol-2-yl, 2,3-dihydrooxazol-3-yl, 2,3-dihydrooxazol-4-yl, 2,3-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, 3,4-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, pyrazynyl, morpholinyl, thiomorphlinyl, l,3-dioxan-5-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, 3-hexahydropyridazinyl, 4-hexahydropyridazinyl, 2-hexahydropyrimidinyl, 4-hexahydropyrimidinyl, 5-hexahydropyrimidinyl, 2-piperazinyl, l,3,5-hexahydrotriazin-2-yl, l,2,4-hexahydrotriazin-3-yl, cycloserines, 2,3,4,5-tetrahydro[1H]azepin-1- or -2- or -3- or -4- or -5- or -6-or -7- yl, 3,4,5,6-tetra-hydro[2H]azepin-2- or -3- or -4- or -5- or -6- or-7-yl, 2,3,4,7-tetrahydro[1H]azepin-1- or -2- or -3- or -4- or -5- or -6- or-7- yl, 2,3,6,7-tetrahydro[1H]azepin-1- or -2- or -3- or -4- or -5- or -6- or -7- yl, hexahydroazepin-1- or -2- or -3- or -4- yl, tetra- and hexahydrooxepinyl such as 2,3,4,5-tetrahydro[1 H]oxepin-2- or -3- or -4- or -5- or -6- or -7- yl, 2,3,4,7-tetrahydro[1H]oxepin-2- or -3- or -4- or -5- or -6- or -7- yl, 2,3,6,7-tetrahydro[1H]oxepin-2-or -3- or -4- or -5- or -6- or -7- yl, hexahydroazepin-1- or -2- or -3- or -4- yl, tetra- and hexahydro-1,3-diazepinyl, tetra- and hexahydro-1,4-diazepinyl, tetra- and hexahydro-1,3-oxazepinyl, tetra- and hexahydro-1,4-oxazepinyl, tetra- and hexahydro-1,3-dioxepinyl, tetra- and hexahydro-1,4-dioxepinyl. This definition also applies to heterocyclyl as a part of a composite substituent, for example heterocyclylalkyl etc., unless specifically defined elsewhere.

The term “heteroaryl” or “aromatic heterocyclic” means 5 or 6-membered, fully unsaturated monocyclic ring system containing one to four heteroatoms from the group of oxygen, nitrogen and sulphur; if the ring contains more than one oxygen atom, they are not directly adjacent; 5-membered heteroaryl containing one to four nitrogen atoms or one to three nitrogen atoms and one sulphur or oxygen atom; 5-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen atoms or one to three nitrogen atoms and one sulphur or oxygen atom as ring members, non-limiting examples furyl, thienyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, l,2,4-oxadiazolyl, l,2,4-thiadiazolyl, l,2,4-triazolyl, l,3,4-oxadiazolyl, l,3,4-thiadiazolyl, l,3,4-triazolyl, tetrazolyl; nitrogen-bonded 5-membered heteroaryl containing one to four nitrogen atoms, or benzofused nitrogen-bonded 5-membered heteroaryl containing one to three nitrogen atoms: 5-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen

atoms or one to three nitrogen atoms as ring members and in which two adjacent carbon ring members or one nitrogen and one adjacent carbon ring member may be bridged by a buta-l,3-diene-l,4-diyl group in which one or two carbon atoms may be replaced by nitrogen atoms, where these rings are attached to the skeleton via one of the nitrogen ring members, non-limiting examples 1-pyrrolyl, 1-pyrazolyl, 1,2,4-triazol-l- yl, 1-imidazolyl, 1,2,3-triazol-l-yl and 1,3,4-triazol-l-yl.

6-membered heteroaryl which contains one to four nitrogen atoms: 6-membered heteroaryl groups which, in addition to carbon atoms, may contain, respectively, one to three and one to four nitrogen atoms as ring members, non-limiting examples 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, l,3,5-triazin-2-yl, l,2,4-triazin-3-yl and l,2,4,5-tetrazin-3-yl; benzofused 5-membered heteroaryl containing one to three nitrogen atoms or one nitrogen atom and one oxygen or sulphur atom: non-limiting examples indol-l-yl, indol-2-yl, indol-3-yl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, benzimidazol-l-yl, benzimidazol-2-yl, benzimidazol-4-yl, benzimidazol-5-yl, indazol-l-yl, indazol-3-yl, indazol-4-yl, indazol-5-yl, indazol-6-yl, indazol-7-yl, indazol-2-yl, l-benzofuran-2-yl, l-benzofuran-3-yl, l-benzofuran-4-yl, l-benzofuran-5-yl, 1-benzofuran- 6-yl, l-benzofuran-7-yl, l-benzothiophen-2-yl, l-benzothiophen-3-yl, l-benzothiophen-4-yl, 1- benzothiophen-5-yl, l-benzothiophen-6-yl, l-benzothiophen-7-yl, l,3-benzothiazol-2-yl, 1,3- benzothiazol-4-yl, l,3-benzothiazol-5-yl, l,3-benzothiazol-6-yl, l,3-benzothiazol-7-yl, l,3-benzoxazol-2-yl, l,3-benzoxazol-4-yl, l,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl and l,3-benzoxazol-7-yl; benzofused 6-membered heteroaryl which contains one to three nitrogen atoms: non-limiting examples quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, isoquinolin-l-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl and isoquinolin-8-yl.

The term “trialkylsilyl” includes 3 branched and/or straight-chain alkyl radicals attached to and linked through a silicon atom such as trimethylsilyl, triethylsilyl and t-butyl-dimethylsilyl. “Halotrialkylsilyl” denotes at least one of the three alkyl radicals is partially or fully substituted with halogen atoms which may be the same or different. The term”alkoxytrialkylsilyl” denotes at least one of the three alkyl radicals is substituted with one or more alkoxy radicals which may be the same or different. The term “trialkylsilyloxy” denotes a trialkylsilyl moiety attached through oxygen.

Non-limiting examples of “alkylcarbonyl” include C(=O)CH3, C(=O)CH2CH2CH3 and C(=O)CH(CH3)2. Non-limiting examples of “alkoxycarbonyl” include CH3OC(=O), CH3CH2OC(=O), CH3CH2CH2OC(=O), (CH3)2CHOC(=O) and the different butoxy -or pentoxycarbonyl isomers. Non-limiting examples of “alkylaminocarbonyl” include CH3NHC(=O), CH3CH2NHC(=O), CH3CH2CH2NHC(=O), (CH3)2CHNHC(=O) and the different butylamino -or pentylaminocarbonyl isomers. Non-limiting examples of “dialkylaminocarbonyl” include (CH3)2NC(=O), (CH3CH2)2NC(=O), CH3CH2(CH3)NC(=O), CH3CH2CH2(CH3)NC(=O) and (CH3)2CHN(CH3)C(=O). Non-limiting examples of “alkoxyalkylcarbonyl” include CH3OCH2C(=O), CH3OCH2CH2C(=O),

CH3CH2OCH2C(=O), CH3CH2CH2CH2OCH2C(=O) and CH3CH2OCH2CH2C(=O). Non-limiting examples of “alkylthioalkylcarbonyl” include CH3SCH2C(=O), CH3SCH2CH2C(=O), CH3CH2SCH2C(=O), CH3CH2CH2CH2SCH2C(=O) and CH3CH2SCH2CH2C(=O). The term haloalkylsufonylaminocarbonyl, alkylsulfonylaminocarbonyl, alkylthioalkoxycarbonyl, alkoxycarbonylalkyl amino and the like are defined analogously

Non-limiting examples of “alkylaminoalkylcarbonyl” include CH3NHCH2C(=O), CH3NHCH2CH2C(=O), CH3CH2NHCH2C(=O), CH3CH2CH2CH2NHCH2C(=O) and CH3CH2NHCH2CH2C(=O).

The term “amide” means A-R'C=ONR''-B, wherein R' and R'' indicates substituents and A and B indicate any group.

The term “thioamide” means A-R'C=SNR''-B, wherein R' and R'' indicates substituents and A and B indicate any group.

The total number of carbon atoms in a substituent group is indicated by the “Ci-Cj” prefix where i and j are numbers from 1 to 21. For example, C1-C3 alkylsulfonyl designates methylsulfonyl through propylsulfonyl; C2 alkoxyalkyl designates CH3OCH2; C3 alkoxyalkyl designates, for example, CH3CH(OCH3), CH3OCH2CH2 or CH3CH2OCH2; and C4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH3CH2CH2OCH2 and CH3CH2OCH2CH2. In the above recitations, when a compound of Formula (I) is comprised of one or more heterocyclic rings, all substituents are attached to these rings through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen. When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents. Further, when the subscript m in (R)m indicates an integer ranging from for example 0 to 4 then the number of substituents may be selected from the integers between 0 and 4 inclusive.

When a group contains a substituent which can be hydrogen, then, when this substituent is taken as hydrogen, it is recognized that said group is being un-substituted.

The embodiments herein and the various features and advantageous details thereof are explained with reference to the non-limiting embodiments in the description. Descriptions of well-known components and processing techniques are omitted so as to not unnecessarily obscure the embodiments herein. The examples used herein are intended merely to facilitate an understanding of ways in which the embodiments herein may be practiced and to further enable those of skilled in the art to practice the embodiments herein. Accordingly, the examples should not be construed as limiting the scope of the embodiments herein.

The description of the specific embodiments will so fully reveal the general nature of the embodiments herein that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. Therefore, while the embodiments herein have been described in terms of preferred embodiments, those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the embodiments as described herein.

Any discussion of documents, acts, materials, devices, articles and the like that has been included in this specification is solely for the purpose of providing a context for the disclosure. It is not to be taken as an admission that any or all of these matters form a part of the prior art base or were common general knowledge in the field relevant to the disclosure as it existed anywhere before the priority date of this application.

The numerical values mentioned in the description and the description/claims though might form a critical part of the present invention of the present invention, any deviation from such numerical values shall still fall within the scope of the present invention if that deviation follows the same scientific principle as that of the present invention disclosed in the present invention.

The inventive compound of the present invention may, if appropriate, be present as mixtures of different possible isomeric forms, especially of stereoisomers, for example E and Z, threo and erythro, and also optical isomers, but if appropriate also of tautomers. Both the E and the Z isomers, and also the threo and erythro isomers, and the optical isomers, any desired mixtures of these isomers and the possible tautomeric forms are disclosed and claimed.

The term “pest” for the purpose of the present disclosure includes but is not limited to fungi, stramenopiles (oomycetes), bacteria, nematodes, mites, ticks, insects and rodents.

The term “plant” is understood here to mean all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants may be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including the plant cultivars which are protectable and non-protectable by plant breeders’ rights.

For the purpose of the present disclosure the term “plant” includes a living organism of the kind exemplified by trees, shrubs, herbs, grasses, ferns, and mosses, typically growing in a site, absorbing water and required substances through its roots, and synthesizing nutrients in its leaves by photosynthesis.

Examples of “plant” for the purpose of the present invention include but are not limited to agricultural crops such as wheat, rye, barley, triticale, oats or rice; beet, e.g. sugar beet or fodder beet; fruits and fruit trees, such as pomes, stone fruits or soft fruits, e.g. apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries, blackberries or gooseberries; leguminous plants, such as lentils, peas, alfalfa or soybeans; oil plants, such as rape, mustard, olives, sunflowers, coconut, cocoa beans, castor oil plants, oil palms, ground nuts or soybeans; cucurbits, such as squashes, cucumber or melons; fiber plants, such as cotton, flax, hemp or jute; citrus fruit and citrus trees, such as oranges, lemons, grapefruits or mandarins; any horticultural plants, vegetables, such as spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, cucurbits or paprika; lauraceous plants, such as avocados, cinnamon or camphor; cucurbitaceae; oleaginous plants; energy and raw material plants, such as cereals, corn, soybean, other leguminous plants, rape, sugar cane or oil palm; tobacco; nuts; coffee; tea; cacao; bananas; peppers; vines (table grapes and grape juice grape vines); hop; turf; sweet leaf (also called Stevia); natural rubber plants or ornamental and forestry plants, such as flowers, shrubs, broad-leaved trees or evergreens, e.g. conifers; and on the plant propagation material, such as seeds, and the crop material of these plants.

Preferably, the plant for the purpose of the present invention includes but is not limited to cereals, corn, rice, soybean and other leguminous plants, fruits and fruit trees, grapes, nuts and nut trees, citrus and citrus trees, any horticultural plants, cucurbitaceae, oleaginous plants, tobacco, coffee, tea, cacao, sugar beet, sugar cane, cotton, potato, tomato, onions, peppers and vegetables, ornamentals, any floricultural plants and other plants for use of human and animals.

The term “plant parts” is understood to mean all parts and organs of plants above and below the ground. For the purpose of the present disclosure the term plant parts includes but is not limited to cuttings, leaves, twigs, tubers, flowers, seeds, branches, roots including taproots, lateral roots, root hairs, root apex, root cap, rhizomes, slips, shoots, fruits, fruit bodies, bark, stem, buds, auxillary buds, meristems, nodes and internodes.

The term “locus thereof” includes soil, surroundings of plant or plant parts and equipment or tools used before, during or after sowing/planting a plant or a plant part.

Application of the compounds of the present disclosure or the compound of the present disclosure in a composition optionally comprising other compatible compounds to a plant or a plant material or locus thereof include application by a technique known to a person skilled in the art which include but is not limited to spraying, coating, dipping, fumigating, impregnating, injecting and dusting.

The term “applied” means adhered to a plant or plant part either physically or chemically including impregnation.

Accordingly, the present invention provides a novel oxadiazole compound formula (I),

wherein,

R1 is C1-C2-haloalkyl;

A is

A1, A2, A3 and A4 are independently selected from CR9 or N;

A5, A6, A7 and A8are independentlyselected from C or N; provided that at least one of A5, A6, A7 and A8 is C;

R9 and R12 are independently selected from the group consisting of hydrogen, halogen, nitro, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl, C1- C6 thioalkyl and C3-C6 cycloalkoxy;

two adjuscent R9 together with the C atom to which they are attached may form a 5- to 6- membered aromatic or non aromatic carbocyclic ring;

Q is selected from the group consisting of Q1 to Q12;

wherein,

R2 and R3 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy andC1-C6 haloalkoxy; or

R2 and R3together with the C atom to which they are attached may form a 3- to 6- membered nonaromatic carbocyclic ring or a 3- to 6- membered nonaromatic heterocyclic ring; wherein the hetero atom is selected from the group consisting of O, S or N; C atom of said nonaromatic carbocyclic ring or said nonaromatic heterocyclic ring may be optionally substituted with C(=O) or C(=S); and said nonaromatic carbocyclic ring or said nonaromatic heterocyclic ring may be optionally substituted with halogen or C1-C3 alkyl or C1-C3-alkoxy; R4, R5, R6, R7, and R8 are independently selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C2-C6-alkenyl, C2-C6-alkynyl,C3-C6cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C3-C6cycloalkyl-C1-C6alkyl, C1-C6alkoxy-C1-C6alkyl,C1-C6 alkoxycarbonyl,C1- C6 alkylsulfinyl, C1-C6 alkylsulfonyl, -(CR10R11)0-4C3-C6 non-aromatic carbocyclyl ring, - (CR10R11)0-4C6-C10 aromatic carbocyclyl ring, -(CR10R11)0-4C3-C6 non-aromatic heterocyclyl ring, -(CR10R11)0-4C6-C10 aromatic heterocyclyl ring, -S(O)0-2C3-C6 non-aromatic carbocyclyl ring, -S(O)0-2C6-C10 aromatic carbocyclyl ring, -S(O)0-2C3-C6 non-aromatic heterocyclyl ring and -S(O)0-2C6-C10 aromatic heterocyclyl ring; or

R4 and R5, R8 and R7, R4 and R6, R5 and R6, R4 and R7 together the atom to which they are attached may represent 4- to 8- membered nonaromatic heterocyclic ring; wherein the hetero atom is selected from the group consisting of O, S(=O)0-2 or NR13; C atom of said nonaromatic heterocyclic ring may be optionally substituted with C(=O) or C(=S);

R4, R5, R6, R7, and R8 are optionally and independently may be substituted with halogen, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, C1-C6haloalkoxy, C1-C6 haloalkyl, C3-C6 cycloalkyl, C3-C6cycloalkyloxy;C1-C6 alkylamino, C1-C6 dialkylamino and C1-C6 trialkylamino;

R10, R11, and R13 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl and C1-C6 alkoxy;

n is an integer selected from 0, 1, 2 or 3;

and/or N-oxides, metal complexes, isomers, polymorphs or the agriculturally acceptable salts thereof. In preferred embodiment, the present invention provides compound of formula (I) wherein

R1 is selected from the group consisting of -CF3, -CHF2 and -CF2Cl;

A is phenyl or pyridyl;

is selected from B1 to B5;

wherein, # represents attachement to A.

In one embodiment, the present invention provides a compound of formula (Ia),

wherein, R1 is CF3; A, R12, n and Q are as defined in the detailed description above.

In another embodiment, the present invention provides a compound of formula (Iaa),

wherein, R1 is CF3;R12, n and Q are as defined in the detailed description above.

In yet another embodiment, the present invention provides a compound of formula (Ib),

wherein, R1 is CF3;A, R12, n and Q are as defined in the detailed description above.

In yet another embodiment, the present invention provides a compound of formula (Iba),

wherein, R1 is CF3;R12, n and Q are as defined in the detailed description above.

In yet another embodiment, the present invention provides a compound of formula (Ic),

wherein, R1 is CF3;A, R12, n and Q are as defined in the detailed description above.

In yet another embodiment, the present invention provides a compound of formula (Ica),

wherein, R1 is CF3;R12, n and Q are as defined in the detailed description above.

In another preferred embodiment, the present invention provides compound of formula (I) is selected from ethyl 2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetate, N-(4-methoxyphenyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, 1-(pyrrolidin-1-yl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)ethan-1-one, N-benzyl-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H- imidazol-4-yl)acetamide, N-(4-methoxybenzyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(4-fluorobenzyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(2-fluorobenzyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(p-tolyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(4-chlorophenyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(3-fluorophenyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, 1-(piperidin-1-yl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)ethan-1-one, N-(3-methoxyphenyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(pyridin-3-yl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(2-bromophenyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-phenyl-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(5-methoxy-2-methylphenyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(4-fluoro-2-methoxyphenyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(4-oxido-1,4-l6-oxathian-4-ylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-(methyl(oxo)(o-tolyl)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-((2-methoxyphenyl)(methyl)(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-((4-methoxyphenyl)(methyl)(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-(methyl(oxo)(phenyl)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-((3-fluorophenyl)(methyl)(oxo)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-(methyl(oxo)(m-tolyl)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, N-((2-methoxyethyl)(oxo)(pyridin-2-yl)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, N-(methyl(oxo)(5-(trifluoromethyl)pyridin-2-yl)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, N-((4-fluorophenyl)(methyl)(oxo)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamid, N-((3-fluoropyridin-4-yl)(methyl)(oxo)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamid, N-((4-methoxypyridin-2-yl)(methyl)(oxo)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, N-(dimethyl(oxo)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, N-((4-methoxyphenyl)(methyl)(oxo)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, N-((2,4-dimethoxyphenyl)(methyl)(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-((2,6-dichlorophenyl)(methyl)(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-

yl)phenyl)-1H-pyrazole-4-carboxamide, N-(methyl(oxo)(pyridin-4-yl)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-((2-methoxyethyl)(methyl)(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-(diethyl(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-(dimethyl(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-((4-chlorophenyl)(methyl)(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-((3-bromophenyl)(isopropyl)(oxo)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, N-(methyl(oxo)(thiazol-2-yl)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, 3-(4-(4-(piperidin-1-ylsulfonyl)-1H-pyrazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-((phenylthio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, tert-Butyl-2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)acetate, N-(4-fluorophenyl)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-ethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-(2,4-difluorophenyl)-N-methyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-(2-fluorophenyl)-N-methyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, 3-(4-(4-(azetidin-1-ylsulfonyl)-1H-pyrazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, N-methyl-N-phenyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-(3-methoxyphenyl)-N-methyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-methyl-N-(p-tolyl)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-(3-fluorophenyl)-N-methyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-(3-chlorophenyl)-N-methyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, 3-(4-(4-((3-fluoropyrrolidin-1-yl)sulfonyl)-1H-pyrazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, N-methyl-N-(pyridin-2-yl)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, 4-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)sulfonyl)morpholine, N-cyclopropyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-benzyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, 3-(4-(4-(((4-methoxyphenyl)thio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-((isopropylthio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((2-fluorophenyl)thio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((4-fluorophenyl)thio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((3-chlorophenyl)thio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((4-methoxybenzyl)thio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-((pyridin-2-ylthio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4- oxadiazole, 3-(4-(4-((phenylsulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((4-methoxyphenyl)sulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-((isopropylsulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((2-fluorophenyl)sulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((4-fluorophenyl)sulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((3-chlorophenyl)sulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((4-methoxybenzyl)sulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-((pyridin-2-ylsulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, imino(phenyl)((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)-l6-sulfanone, (2-fluorophenyl)(imino)((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)-l6-sulfanone, 4-methyl-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)benzenesulfonamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)benzenesulfonamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)acetamide, 4-fluoro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)benzenesulfonamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)cyclopropanesulfonamide, 4-(trifluoromethyl)-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)benzamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)isobutyramide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)cyclobutanecarboxamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)benzamide, 4-methoxy-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)benzamide, 2-fluoro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)benzamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)methanesulfonamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)thiazole-2-carboxamide, 2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)-N-phenylacetamide, N-(4-Chlorophenyl)-2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)acetamide, 2-(3,5-Dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)-N-(4-fluoro-2-methoxyphenyl)acetamide, 2-(3,5-Dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)-N-(pyridin-2-yl)acetamide, 2-(3,5-Dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)-N-(thiazol-2-yl)acetamide, N-(4-Chloro-3-fluorophenyl)-2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)acetamide, N-(4-Chlorobenzyl)-2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)acetamide, 4-chloro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)benzamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4- yl)methyl)acetamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)propionamide, 2-fluoro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)benzamide, 4-fluoro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)benzamide, 2-methyl-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)thiazole-5-carboxamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)cyclobutanecarboxamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)nicotinamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)methanesulfonamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)ethanesulfonamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)cyclopropanesulfonamide, 2-fluoro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)benzenesulfonamide, 5-chloro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)thiophene-2-sulfonamide, 4-fluoro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)benzenesulfonamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)pyridine-3-sulfonamide, 1-(pyridin-3-yl)-3-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)urea, 1-(2-fluorophenyl)-3-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)urea, (4-fluorophenyl)(imino)((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)-l6-sulfanone, (3-chlorophenyl)(imino)((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)-l6-sulfanone, 2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)-N-(2-methoxyethyl)acetamide, N-(cyclopropylmethyl)-2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)acetamide, N-cyclopropyl-2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)acetamide, 3-(4-(4-(((4-fluorophenyl)sulfinyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-((phenylsulfinyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, (2-fluorophenyl)(methyl)(((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)imino)-l6-sulfanone, (4-methoxyphenyl)(methyl)(((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)imino)-l6-sulfanone, methyl(thiazol-2-yl)(((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)imino)-l6-sulfanone, methyl(pyridin-4-yl)(((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)imino)-l6-sulfanone and methyl(phenyl)(((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)imino)-l6-sulfanone.

In one embodiment, the present invention provides a compound of formula (II),

wherein,

G is -CN or -C(NH2)=N-OH;

A, A5, A6, A7, A8, R12, n and Q are as defined in above.

In one embodiment, the present invention provides a compound of formula (III),

wherein,

R1 is C1-C2 haloalkyl;

A5, A6, A7 and A8 are independently selected from CR9 or N; provided that at least one of A5, A6, A7 and A8 is CR9;

R9 is selected from the group consisting of hydrogen, halogen, nitro, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl and C3-C6 cycloalkoxy; -S(O)2Cl, C1-C6 alkylamino, C1-C6 dialkylamino and C1-C6 trialkylamino.

The compound of the present invention can exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers. The compound of the present invention may be present as a mixture of stereoisomers, individual stereoisomers or as an optically active form.

An anion part of the salt in case the compound of formula (I) is a cationic or capable of forming a cation can be inorganic or organic. Alterntively, a cation part of the salt in case the compound of formula (I) is an anionic or capable of forming anion can be inorganic or organic. Examples of

inorganic anion part of the salt include but are not limited to chloride, bromide, iodide, fluoride, sulphate, phosphate, nitrate, nitrite, hydrogen carbonates, hydrogensulphate. Examples of organic anion part of the salt include but are not limited to formate, alkanoates, carbonates, acetates, trifluoroacetate, trichloroacetate, propionate, glycolate, thiocyanate, lactate, succinate, malate, citrates, benzoates, cinnamates, oxalates, alkylsulphates, alkylsulphonates, arylsulphonates aryldisulphonates, alkylphosphonates, arylphosphonates, aryldiphosphonates, p-toluenesulphonate, and salicylate. Examples of inorganic cation part of the salt include but are not limited to alkali and alkaline earth metals. Examples of organic cation part of the salt include but are not limited to pyridine, methyl amine, imidazole, benzimidazole, hitidine, phosphazene, tetramethyl ammonium, tetrabutylammonium, choline and trimethylamine.

Metal ions in metal complexes of the compound of formula (I) are especially the ions of the elements of the second main group, especially calcium and magnesium, of the third and fourth main group, especially aluminium, tin and lead, and also of the first to eighth transition groups, especially chromium, manganese, iron, cobalt, nickel, copper, zinc and others. Particular preference is given to the metal ions of the elements of the fourth period and the first to eighth transition groups. Here, the metals can be present in the various valencies that they can assume.

The compound selected from formula (I), (including all stereoisomers, N-oxides, and salts thereof), typically may exist in more than one form. Formula (I) thus includes all crystalline and non-crystalline forms of the compound that formula (I) represents. Non-crystalline forms include embodiments which are solids such as waxes and gums as well as embodiments which are liquids such as solutions and melts. Crystalline forms include embodiments which represent essentially a single crystal type and embodiments which represent a mixture of polymorphs (i.e. different crystalline types). The term "polymorph" refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the molecules in the crystal lattice. Although polymorphs can have the same chemical composition, they can also differ in composition due to the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability. One skilled in the art will appreciate that a polymorph of a compound represented by formula (I) can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound represented by formula (I). Preparation and isolation of a particular polymorph of a compound represented by formula (I) can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures.

CLAIMS:

1) A compound formula (I),

wherein,

R1 is C1-C2-haloalkyl;

A is

A1, A2, A3 and A4 are independently selected from CR9 or N;

A5, A6, A7 and A8are independentlyselected from Cor N; provided that at least one of A5, A6, A7 and A8 is C;

R9 and R12 are independently selected from the group consisting of hydrogen, halogen, nitro, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl, C1- C6 thioalkyl and C3-C6 cycloalkoxy;

two adjuscent R9 together with the C atom to which they are attached may form a 5- to 6- membered aromatic and non aromatic carbocyclic ring;

Q is selected from the group consisting of Q1 to Q12;

wherein,

R2 and R3 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy andC1-C6 haloalkoxy; or

R2 and R3together with the C atom to which they are attached may form a 3- to 6- membered nonaromatic carbocyclic ring or a 3- to 6- membered nonaromatic heterocyclic ring; wherein the hetero atom is selected from the group consisting of O, S or N; C atom of said nonaromatic carbocyclic ring or said nonaromatic heterocyclic ring may be optionally substituted with C(=O) or C(=S); and said nonaromatic carbocyclic ring or said nonaromatic heterocyclic ring may be optionally substituted with halogen or C1-C3 alkyl or C1-C3-alkoxy; R4, R5, R6, R7, and R8 are independently selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C2-C6-alkenyl, C2-C6-alkynyl,C3-C6cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C3-C6cycloalkyl-C1-C6alkyl, C1-C6alkoxy-C1-C6alkyl,C1-C6 alkoxycarbonyl,C1- C6 alkylsulfinyl, C1-C6 alkylsulfonyl, -(CR10R11)0-4C3-C6 non-aromatic carbocyclyl ring, - (CR10R11)0-4C6-C10 aromatic carbocyclyl ring, -(CR10R11)0-4C3-C6 non-aromatic heterocyclyl ring, -(CR10R11)0-4C6-C10 aromatic heterocyclyl ring, -S(O)0-2C3-C6 non-aromatic carbocyclyl ring, -S(O)0-2C6-C10 aromatic carbocyclyl ring, -S(O)0-2C3-C6 non-aromatic heterocyclyl ring and -S(O)0-2C6-C10 aromatic heterocyclyl ring; or

R4 and R5, R8 and R7, R4 and R6, R5 and R6, R4 and R7 together the atom to which they are attached may represent 4- to 8- membered nonaromatic heterocyclic ring; wherein the hetero atom is selected from the group consisting of O, S(=O)0-2 or NR13; C atom of said nonaromatic heterocyclic ring may be optionally substituted with C(=O) or C(=S);

R4, R5, R6, R7, and R8 are optionally and independently may be substituted with halogen, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, C1-C6haloalkoxy, C1-C6 haloalkyl, C3-C6 cycloalkyl, C3-C6cycloalkyloxy;C1-C6 alkylamino, C1-C6 dialkylamino and C1-C6 trialkylamino;

R10, R11, and R13 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl and C1-C6 alkoxy;

n is an integer selected from 0, 1, 2 or 3;

and/or N-oxides, metal complexes, isomers, polymorphs or the agriculturally acceptable salts thereof.

2) The compound formula (I) according to claim 1, wherein

R1 is selected from the group consisting of -CF3, -CHF2 and -CF2Cl;

A is phenyl or pyridyl;

is selected from B1 to B5;

wherein, # represents attachement to A.

3) The compound of formula (I) according toclaim 1, wherein said compound of formula (I) is selected from ethyl 2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4- yl)acetate, N-(4-methoxyphenyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H- imidazol-4-yl)acetamide, 1-(pyrrolidin-1-yl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl)phenyl)-1H-imidazol-4-yl)ethan-1-one, N-benzyl-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol- 3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(4-methoxybenzyl)-2-(1-(4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(4-fluorobenzyl)-2-(1-(4-(5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(2-fluorobenzyl)- 2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(p- tolyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N- (4-chlorophenyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4- yl)acetamide, N-(3-fluorophenyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H- imidazol-4-yl)acetamide, 1-(piperidin-1-yl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl)phenyl)-1H-imidazol-4-yl)ethan-1-one, N-(3-methoxyphenyl)-2-(1-(4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(pyridin-3-yl)-2-(1-(4-(5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(2-bromophenyl)- 2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-phenyl- 2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(5- methoxy-2-methylphenyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H- imidazol-4-yl)acetamide, N-(4-fluoro-2-methoxyphenyl)-2-(1-(4-(5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)acetamide, N-(4-oxido-1,4-l6-oxathian-4-ylidene)-1-(4- (5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N- (methyl(oxo)(o-tolyl)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)- 1H-pyrazole-4-carboxamide, N-((2-methoxyphenyl)(methyl)(oxo)-l6-sulfaneylidene)-1-(4-(5-

(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-((4-methoxyphenyl)(methyl)(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-(methyl(oxo)(phenyl)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-((3-fluorophenyl)(methyl)(oxo)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-(methyl(oxo)(m-tolyl)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, N-((2-methoxyethyl)(oxo)(pyridin-2-yl)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, N-(methyl(oxo)(5-(trifluoromethyl)pyridin-2-yl)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, N-((4-fluorophenyl)(methyl)(oxo)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamid, N-((3-fluoropyridin-4-yl)(methyl)(oxo)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamid, N-((4-methoxypyridin-2-yl)(methyl)(oxo)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, N-(dimethyl(oxo)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, N-((4-methoxyphenyl)(methyl)(oxo)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, N-((2,4-dimethoxyphenyl)(methyl)(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-((2,6-dichlorophenyl)(methyl)(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-(methyl(oxo)(pyridin-4-yl)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-((2-methoxyethyl)(methyl)(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-(diethyl(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-(dimethyl(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-((4-chlorophenyl)(methyl)(oxo)-l6-sulfaneylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-carboxamide, N-((3-bromophenyl)(isopropyl)(oxo)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, N-(methyl(oxo)(thiazol-2-yl)-l6-sulfanylidene)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-3-carboxamide, 3-(4-(4-(piperidin-1-ylsulfonyl)-1H-pyrazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-((phenylthio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, tert-Butyl-2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)acetate, N-(4-fluorophenyl)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-ethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-(2,4-difluorophenyl)-N-methyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl)phenyl)-1H-pyrazole-4-sulfonamide, N-(2-fluorophenyl)-N-methyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, 3-(4-(4-(azetidin-1-ylsulfonyl)-1H-pyrazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, N-methyl-N-phenyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-(3-methoxyphenyl)-N-methyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-methyl-N-(p-tolyl)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-(3-fluorophenyl)-N-methyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-(3-chlorophenyl)-N-methyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, 3-(4-(4-((3-fluoropyrrolidin-1-yl)sulfonyl)-1H-pyrazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, N-methyl-N-(pyridin-2-yl)-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, 4-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)sulfonyl)morpholine, N-cyclopropyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, N-benzyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazole-4-sulfonamide, 3-(4-(4-(((4-methoxyphenyl)thio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-((isopropylthio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((2-fluorophenyl)thio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((4-fluorophenyl)thio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((3-chlorophenyl)thio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((4-methoxybenzyl)thio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-((pyridin-2-ylthio)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-((phenylsulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((4-methoxyphenyl)sulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-((isopropylsulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((2-fluorophenyl)sulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((4-fluorophenyl)sulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((3-chlorophenyl)sulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-(((4-methoxybenzyl)sulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-((pyridin-2-ylsulfonyl)methyl)-1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, imino(phenyl)((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)-l6-sulfanone, (2-fluorophenyl)(imino)((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)-l6-sulfanone, 4-methyl-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)benzenesulfonamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)benzenesulfonamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)acetamide, 4-fluoro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)benzenesulfonamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)cyclopropanesulfonamide, 4-(trifluoromethyl)-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)benzamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)isobutyramide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)cyclobutanecarboxamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)benzamide, 4-methoxy-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)benzamide, 2-fluoro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)benzamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)methanesulfonamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4-yl)methyl)thiazole-2-carboxamide, 2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)-N-phenylacetamide, N-(4-Chlorophenyl)-2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)acetamide, 2-(3,5-Dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)-N-(4-fluoro-2-methoxyphenyl)acetamide, 2-(3,5-Dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)-N-(pyridin-2-yl)acetamide, 2-(3,5-Dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)-N-(thiazol-2-yl)acetamide, N-(4-Chloro-3-fluorophenyl)-2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)acetamide, N-(4-Chlorobenzyl)-2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)acetamide, 4-chloro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)benzamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)acetamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)propionamide, 2-fluoro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)benzamide, 4-fluoro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)benzamide, 2-methyl-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)thiazole-5-carboxamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)cyclobutanecarboxamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)nicotinamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)methanesulfonamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)ethanesulfonamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)cyclopropanesulfonamide, 2-fluoro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)benzenesulfonamide, 5-chloro-N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)thiophene-2-sulfonamide, 4-fluoro-N-((1- (4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4- yl)methyl)benzenesulfonamide, N-((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H- pyrazol-4-yl)methyl)pyridine-3-sulfonamide, 1-(pyridin-3-yl)-3-((1-(4-(5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)urea, 1-(2-fluorophenyl)-3-((1-(4-(5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)urea, (4- fluorophenyl)(imino)((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-imidazol-4- yl)methyl)-l6-sulfanone, (3-chlorophenyl)(imino)((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl)phenyl)-1H-imidazol-4-yl)methyl)-l6-sulfanone, 2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)-N-(2-methoxyethyl)acetamide, N- (cyclopropylmethyl)-2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H- pyrazol-4-yl)acetamide, N-cyclopropyl-2-(3,5-dimethyl-1-(4-(5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)acetamide, 3-(4-(4-(((4-fluorophenyl)sulfinyl)methyl)- 1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, 3-(4-(4-((phenylsulfinyl)methyl)- 1H-imidazol-1-yl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole, (2-fluorophenyl)(methyl)(((1-(4- (5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)imino)-l6-sulfanone, (4-methoxyphenyl)(methyl)(((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol- 4-yl)methyl)imino)-l6-sulfanone, methyl(thiazol-2-yl)(((1-(4-(5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)imino)-l6-sulfanone, methyl(pyridin-4-yl)(((1-(4- (5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4-yl)methyl)imino)-l6-sulfanone and methyl(phenyl)(((1-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrazol-4- yl)methyl)imino)-l6-sulfanone.

4) A combination comprising the compound of formula (I) according toclaim 1 and at least one further pesticidally active substance selected from the group consisting of fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, safeners, plant growth regulators, antibiotics, fertilizers and nutrients.

5) Anagrochemical composition comprising the compound of formula (I) according toclaim 1 and at least one agrochemically acceptable auxiliary.

6) The composition according toclaim 5, wherein said composition may further comprises at least one additional active ingredient.

7) The composition according toclaim 5, wherein said composition is applied to seed and the amount of compound of the formula (I) in said composition ranges from 0.1 gai to 10 kgai per 100 kg of seeds.

8) A method for controlling or preventing phytopathogenic microorganisms, wherein the method comprises treating the fungi or the materials, plants, plant parts, locus thereof, soil or seeds to be protected against fungal attack, with an effective amount of at least one compound of formula (I) according toclaim 1 or the combination according toclaim 4 or the composition according toclaim 5.

9) A method for controlling or preventing infestation of plants by phytopathogenic microorganisms in agricultural crops and/or horticultural crops wherein an effective amount of at least one compound of formula (I) as claimed in claim 1 or the combination according toclaim 4 or the composition according toclaim 5, is applied to the plants, to parts thereof or locus thereof.

10) A method according toclaim 9, wherein the phytopathogenic microorganisms are selected from the group comprising of Hemileia vastatrix (Coffee rust), Uromyces appendiculatus/fabae/ phaseoli (rust of beans) Puccinia spp. (rusts) on various plants selected from P. triticina (brown or leaf rust), P. striiformis (stripe or yellow rust), P. Hordei (dwarf rust), P. graminis (stem or black rust) or P. recondita (brown or leaf rust) on cereals selected from wheat, barley or rye and Phakopsora spp. on various plants, in particular Phakopsora pachyrhizi and P. meibomiae (soybean rust) on soybeans.

11) Use of a compound of formula (I) according toclaim 1 as a fungicide.

12) A process for the synthesis of compound of formula (I) according toclaim 1, wherein said process comprising at least one of the following steps (a) to (m):

a) reacting a compound of formula 3 with a hydroxyl amine to afford a compound of formula 4;

wherein, R12, A,A5, A6,A7and A8 are as defined in claim 1; Q is Q is Q3, Q6, Q7, Q11, H, CR2R3N(Boc)2, or CR2R3SR7 and provided that R12 is not cyano;

b) reacting the compound of formula 4 with a suitable carboxylic acid anhydride of formula 5 to afford a compound of formula (I);

wherein, R1, R12, A,A5, A6, A7and A8 are as defined in claim 1; Q is Q3, Q6, Q7, Q11, H, CR2R3N(Boc)2, or CR2R3SR7; provided that R12 is not cyano;

c) reacting a compound of formula 6 with a compound of formula 7 to afforda compound of formula (I);

wherein, R1, R12, A,A5, A6, A7 and A8 are as defined in claim 1; Q is Q1;

d) reacting a compound of formula 12 with a compound of formula 2d to afford a compound of formula (I);

wherein, R1, R12, A,A5, A6, A7and A8 are as defined in claim 1; Q is Q4;

e) reacting a compound of formula 16 with a chlorosulphonic acid to afford a compound of formula 17;

wherein, R1, R12, A,A5, A6and A8 are as defined in claim 1;A7 is CH; and R12 is not cyano;

f) reacting a compound of formula 17 with a suitable amine of formula NHR4R5to afford a compound of formula (I);

wherein, R1,R4,R5,R12, A,A5, A6and A8 are as defined in claim 1; Q is Q6; A7 is CH; and R12 is not cyano;

g) reacting a compound of formula 21 with a compound of formula 2h to afford a compound of formula 22;

wherein, R7, R8, R12, A,A5, A6, A7 and A8 are as defined in claim 1;

h) reacting the compound of formula 22 with a hydroxyl amine to afford a compound of formula 23;

wherein, R7, R8, R12, A,A5, A6, A7and A8 are as defined in claim 1;

i) reacting a compound of formula 23 with a compound of formula 5 to afford a compound of formula (I);

wherein, R1, R7, R8, R12, A,A5, A6, A7and A8 are as defined in claim 1; Q is Q5;

j) reacting a compound of formula 26 with a suitable acid to afford a compound of formula 27;

wherein, R1, R12, A,A5, A6, A7 and A8 are as defined in claim 1;

k) reacting the compound of formula 27 with a compound of formula 2e or 2fto afford a compound of formula (I);

wherein, R1, R6, R12, A,A5, A6, A7and A8 are as defined in claim 1; Q is Q2;

l) reactingthe compound of formula 27 with a compound formula 2g to afford a compound of formula (I);

wherein, R1,R12, A,A5, A6, A7 and A8 are as defined in claim 1; Q is Q8;

m) reacting a compound of formula 30 with a ammonia source reagentin the presence suitable oxidizing agent to afford a compound of formula (I);

wherein, R1, R7, R12, A,A5, A6, A7 and A8 are as defined in claim 1; Q is Q3.

13) A compound of formula (II),

wherein,

G is -CN or -C(NH2)=N-OH;

A, A5, A6, A7, A8, R12, n and Q are as defined in claim 1.

14) A compound of formula (III),

wherein,

R1is C1-C2 haloalkyl;

A5, A6, A7 and A8 are independently selected from CR9 or N; provided that at least one of A5, A6, A7 and A8 is CR9;

R9 is selected from the group consisting of hydrogen, halogen, nitro, cyano, C1-C6 alkyl, C1- C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl and C3-C6 cycloalkoxy;- S(O)2Cl,C1-C6 alkylamino, C1-C6 dialkylamino and C1-C6 trialkylamino;

or salt thereof.